撰文丨王聪 编辑丨王多鱼 排版丨水成文 司美格鲁肽 （Semaglutide） 是 诺和诺德 公司开发的一款降糖药物，用于治疗 2 型糖尿病，2021 年 6 月， FDA 批准了司美格鲁肽作为 减肥药 上市 （商品名为Wegovy） 。该药物是一种胰高血糖素样肽-1 （GLP-1） 受体激动剂，能够模拟其作用，减少饥饿感，从而减少饮食、减少热量摄入，因此在减肥方面 效果突出。 除了用于 治疗 2型糖尿病 和 肥胖 ，司美格鲁肽还被发现能够保护心血管健康、降低癌症风 险、帮助戒酒等。 2024 年 10 月， 《 新英格兰医学杂志 》 （NEJM） 发表的临床研究论文显示，司美格鲁肽 能够显著减 轻体重，并显著减轻肥胖相关的 膝关节炎 引起的疼痛 ， 并提高他们参与运动的能力，首次证实了 GLP-1 受体激动剂类新型减肥药物可以治疗骨关节炎。 然而，司美格鲁肽的这种骨关节炎治疗效果，是源于体重减轻导致的关节负荷减少，还是源于其抗炎作 用，亦或是二者兼而有之，目前尚不完全清楚。 2026 年 2 月 9 日， 中国科学院深圳先进技术研究院 童丽萍 研究员、 陈棣 教授、 John R. Speakman 教授及 ...

Core Viewpoint - The article discusses a significant advancement in the development of disease-modifying osteoarthritis drugs (DMOADs) through a novel drug delivery system that effectively targets diseased chondrocytes, addressing major challenges in osteoarthritis treatment [1][2]. Group 1 - A multifunctional peptide (CMP) mimicking viral glycoproteins was developed to enhance drug delivery to osteoarthritic chondrocytes, overcoming issues related to cartilage penetration, retention, and selective uptake by diseased cells [2][5]. - The research team synthesized CMP, which includes a type II collagen adhesion sequence and a cell-penetrating peptide activated by matrix metalloproteinase-13, allowing the drug-loaded micelles to adhere to cartilage and selectively target diseased chondrocytes [5]. - In mouse models of osteoarthritis, the developed micelles demonstrated longer joint retention times and higher uptake rates in diseased chondrocytes compared to unmodified micelles, indicating improved efficacy [5]. Group 2 - The drug delivery system maintained cartilage metabolic homeostasis, alleviated pathological changes associated with osteoarthritis, and improved symptoms without causing additional toxicity [2][5]. - Overall, the findings suggest that the developed nanomedicine represents a promising candidate for DMOADs and provides an efficient delivery strategy for targeting other therapeutic agents to diseased chondrocytes [2][5].

Core Viewpoint - Osteoarthritis (OA) is a degenerative joint disease primarily affecting the elderly, characterized by the degradation of articular cartilage and subsequent joint pain and limited mobility. Current treatments include non-steroidal anti-inflammatory drugs and, in severe cases, total joint replacement [2]. Group 1: Treatment Innovations - The FDA has recently approved Matrix-associated Autologous Chondrocyte Implantation (MACI) for repairing isolated cartilage injuries in patients aged 18-55, indicating that cell therapy may become an effective treatment for osteoarthritis [3]. - Procr chondroprogenitors, identified in a study published in Cell, are sensitive to mechanical stimuli and play a crucial role in maintaining and regenerating articular cartilage, presenting a promising cell source for treating degenerative orthopedic diseases like osteoarthritis [4][9]. Group 2: Research Findings - The study found that mechanical stimulation from forced running significantly increased the number of Procr+ cells, while mechanical unloading decreased their numbers. OA activates Procr+ cells to repair cartilage erosion, and their genetic knockout accelerates OA progression [6]. - Inhibition of the mechanosensor Piezo1 significantly impairs the cartilage repair function of Procr+ cells, while intra-articular injection of Piezo1 agonists improves OA symptoms [6]. - Purified Procr+ superficial cells, after expansion and in vivo transplantation, can effectively repair cartilage defects, highlighting their potential as a reliable cell source for treating knee joint diseases like osteoarthritis [9].

Core Viewpoint - Yifan Pharmaceutical's product Yinikang (Dinggan Cross-linked Sodium Hyaluronate Injection) is in a rapid growth phase, with significant market potential in the treatment of osteoarthritis, particularly among the aging population in China [1][2] Group 1: Product Development and Market Position - Yifan Pharmaceutical has obtained exclusive import and distribution rights for Yinikang in China and Australia, and the product received its drug registration certificate in April 2023, allowing for official sales in China [1] - The product is expected to be included in the new national medical insurance directory by December 2023, enhancing accessibility and affordability of innovative drugs [1] - The market for osteoarthritis treatment in China is projected to reach between 102 billion to 170 billion RMB, indicating substantial growth potential for Yifan's Yinikang product [2] Group 2: Financial Performance and Growth Strategy - Yifan Pharmaceutical achieved a revenue of 5.16 billion RMB in 2024, marking a year-on-year growth of 26.84%, with domestic revenue at 3.85 billion RMB (up 34.88%) and international revenue at 1.31 billion RMB (up 7.87%) [4] - The company is focusing on internationalization, having successfully entered the EU market with its Amikacin Sulfate Injection, marking a significant milestone in its global strategy [5] - Yifan aims to increase the number of major products generating over 10 million RMB in annual sales from 29 to 35 by 2025, with specific targets for products exceeding 50 million and 100 million RMB [7] Group 3: Competitive Advantages and Future Outlook - Yifan Pharmaceutical has established a comprehensive production and sales network, positioning itself as one of the few domestic companies with a complete closed-loop capability in the pharmaceutical industry [3] - The company emphasizes innovation and internationalization as core strategies, leveraging its experience in clinical trials and regulatory processes to enhance its product line and market competitiveness [6][7] - With ongoing innovation and market expansion, Yifan is expected to achieve continuous breakthroughs in both domestic and international pharmaceutical markets [7]

Core Viewpoint - The research team at Tianjin University has developed a novel streamlined zinc oxide composite injectable hydrogel that opens new pathways for the treatment of osteoarthritis and cartilage regeneration [1][2] Group 1: Hydrogel Characteristics - The hydrogel exhibits dual characteristics of being "smooth during injection" and "firm after implantation" [1] - The streamlined zinc oxide structure optimizes the rheological and mechanical properties of the hydrogel, providing high mechanical strength and low flow viscosity [1][2] Group 2: Mechanism and Functionality - The hydrogel addresses the critical issue of extracellular matrix homeostasis imbalance in osteoarthritis treatment by incorporating matrix metalloproteinase-responsive features and delivering the miR-17-5p gene drug [1] - miR-17-5p is a small RNA molecule that effectively inhibits the overactive matrix metalloproteinases responsible for excessive degradation of the extracellular matrix [1] Group 3: Injection and Performance - The internal streamlined zinc oxide nanoparticles reduce fluid resistance during injection, allowing for smoother passage through the injection needle and rapid filling of irregular tissue defects [2] - Upon injection, the hydrogel undergoes a cross-linking reaction, forming a stronger network structure that enhances its mechanical performance and resistance to external mechanical stress [2] Group 4: Gene Therapy Implications - The streamlined structure significantly improves the transfection efficiency of miR-17-5p, providing new insights for precise delivery in gene therapy [2] - This design not only reduces energy loss during the injection process but also greatly enhances the hydrogel's supporting capacity at tissue defect sites, ensuring long-term treatment efficacy and structural integrity [2]